JS 105
Alternative Names: JS-105; RP-903Latest Information Update: 18 Aug 2025
At a glance
- Originator Risen Pharma
- Developer Risen Pharma; Shanghai Junshi Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Solid tumours
- Phase I Breast cancer; Congenital abnormalities
Most Recent Events
- 18 Aug 2025 Phase-I clinical trials in Congenital-abnormalities in China (PO), prior to August 2025 (Risen Pharma pipeline, August 2025)
- 18 Aug 2025 Phase-II/III clinical trials in Solid tumours (Late-stage disease) in China (PO), prior to August 2025 (Risen Pharma pipeline, August 2025)
- 18 Aug 2025 Phase-II/III clinical trials in Solid tumours (Late-stage disease) in USA (PO), prior to August 2025 (Risen Pharma pipeline, August 2025)